Fenretinide Acts as Potent Radiosensitizer for Treatment of Rhabdomyosarcoma Cells

by Eva Brack, Eva Brack, Eva Brack, Sabine Bender, Marco Wachtel, Marco Wachtel, Martin Pruschy, Beat W. Schäfer, Beat W. Schäfer
Published 2021-06-01

A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurre...

by Gabriele Manzella, Devmini C. Moonamale, Michaela Römmele, Peter Bode, Marco Wachtel, Beat W. Schäfer
Published 2021-09-01

NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency

by Joana G Marques, Berkley E Gryder, Blaz Pavlovic, Yeonjoo Chung, Quy A Ngo, Fabian Frommelt, Matthias Gstaiger, Young Song, Katharina Benischke, Dominik Laubscher, Marco Wachtel, Javed Khan, Beat W Schäfer
Published 2020-08-01

Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage

by Berkley E. Gryder, Marco Wachtel, Kenneth Chang, Osama El Demerdash, Nicholas G. Aboreden, Wardah Mohammed, Winston Ewert, Silvia Pomella, Rossella Rota, Jun S. Wei, Young Song, Benjamin Z. Stanton, Beat Schäfer, Christopher R. Vakoc, Javed Khan
Published 2020-05-01

Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

by Gabriele Manzella, Leonie D. Schreck, Willemijn B. Breunis, Jan Molenaar, Hans Merks, Frederic G. Barr, Wenyue Sun, Michaela Römmele, Luduo Zhang, Joelle Tchinda, Quy A. Ngo, Peter Bode, Olivier Delattre, Didier Surdez, Bharat Rekhi, Felix K. Niggli, Beat W. Schäfer, Marco Wachtel
Published 2020-09-01